Published in J Natl Cancer Inst on December 11, 2007
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers Prev (2014) 2.36
A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol (2014) 1.79
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int (2012) 1.68
Fatherhood and incident prostate cancer in a prospective US cohort. Int J Epidemiol (2010) 1.63
Consumption of fish products across the lifespan and prostate cancer risk. PLoS One (2013) 1.46
Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev (2008) 1.44
Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med (2009) 1.26
Prostate cancer screening: current status and future perspectives. Nat Rev Urol (2010) 1.23
Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer (2015) 1.04
Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res (2012) 1.03
Male infertility: a risk factor for testicular cancer. Nat Rev Urol (2009) 1.02
What do prostate cancer patients die of? Oncologist (2011) 0.95
Dietary zinc and prostate cancer survival in a Swedish cohort. Am J Clin Nutr (2011) 0.94
One-carbon metabolism-related nutrients and prostate cancer survival. Am J Clin Nutr (2009) 0.91
Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology (2014) 0.89
Prostate-specific antigen screening: pro. Curr Opin Urol (2010) 0.88
Milk intake in early life and risk of advanced prostate cancer. Am J Epidemiol (2011) 0.88
Early detection of prostate cancer: is screening in general practice justifiable? Scand J Prim Health Care (2011) 0.86
PALB2 variants in hereditary and unselected Finnish prostate cancer cases. J Negat Results Biomed (2009) 0.86
Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol (2009) 0.85
Homogeneous prostate cancer mortality in the Nordic countries over four decades. Eur Urol (2010) 0.85
Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate. J Oncol (2014) 0.81
Prediagnostic Serum Organochlorine Concentrations and Metastatic Prostate Cancer: A Nested Case-Control Study in the Norwegian Janus Serum Bank Cohort. Environ Health Perspect (2015) 0.80
Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals? Eur J Epidemiol (2016) 0.79
Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. Cancer Causes Control (2012) 0.78
How should prostate specific antigen be interpreted? Turk J Urol (2013) 0.77
A critical review of the epidemiology of Agent Orange/TCDD and prostate cancer. Eur J Epidemiol (2014) 0.77
Model-based patterns in prostate cancer mortality worldwide. Br J Cancer (2013) 0.76
Environment as a potential key determinant of the continued increase of prostate cancer incidence in martinique. Prostate Cancer (2011) 0.75
Methods and rationale used in a matched cohort study of the incidence of new primary cancers following prostate cancer. Clin Epidemiol (2013) 0.75
Incidence variation of prostate and cervical cancer according to socioeconomic level in the Girona Health Region. BMC Public Health (2014) 0.75
A comparative population-based study of prostate cancer incidence and mortality rates in Singapore, Sweden and Geneva, Switzerland from 1973 to 2006. BMC Cancer (2012) 0.75
National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis. World J Urol (2016) 0.75
Prostate cancer incidence as an iceberg. Eur J Epidemiol (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet (2008) 12.43
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med (2010) 8.71
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
International variation in prostate cancer incidence and mortality rates. Eur Urol (2012) 8.04
Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med (2012) 7.78
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol (2008) 7.18
The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 6.61
Predicting the future burden of cancer. Nat Rev Cancer (2006) 6.10
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48
Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med (2014) 5.05
Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer (2008) 5.00
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet (2012) 4.76
Non-communicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol (2011) 4.74
Cancer mortality in India: a nationally representative survey. Lancet (2012) 4.30
Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer (2005) 4.24
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2012) 4.07
Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study. BMJ (2012) 4.05
Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer (2002) 4.02
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol (2009) 3.92
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet (2007) 3.84
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer (2005) 3.81
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. BMJ (2004) 3.67
Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer (2009) 3.67
Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med (2012) 3.56
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol (2011) 3.45
The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer (2007) 3.44
Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev (2002) 3.40
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol (2008) 3.29
A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst (2003) 3.29
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology (2014) 3.06
Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet (2011) 3.06
Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol (2013) 3.00
Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974-2003. J Natl Cancer Inst (2009) 2.90
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Feasibility of using web-based questionnaires in large population-based epidemiological studies. Eur J Epidemiol (2006) 2.86
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol (2013) 2.84
Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med (2003) 2.81
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology (2005) 2.80
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet (2002) 2.72
Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer (2006) 2.71
Balancing the harms and benefits of early detection of prostate cancer. Cancer (2010) 2.71
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol (2012) 2.62
Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol (2009) 2.59
Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat Genet (2009) 2.58
Average energy intake among pregnant women carrying a boy compared with a girl. BMJ (2003) 2.55
Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature (2013) 2.55
A national strategic change in treatment policy for rectal cancer--implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum (2002) 2.53
Cancer burden in Africa and opportunities for prevention. Cancer (2012) 2.51
Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst (2007) 2.49
NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol (2010) 2.48
Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med (2012) 2.45
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst (2002) 2.44
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
The Finnish Cancer Registry as follow-up source of a large trial cohort--accuracy and delay. Acta Oncol (2002) 2.40
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40